153 related articles for article (PubMed ID: 38791382)
1. Clinical and Immunologic Characteristics of Colorectal Cancer Tumors Expressing LY6G6D.
Sanvicente García A; Pedregal M; Paniagua-Herranz L; Díaz-Tejeiro C; Nieto-Jiménez C; Pérez Segura P; Munkácsy G; Győrffy B; Calvo E; Moreno V; Ocaña A
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791382
[TBL] [Abstract][Full Text] [Related]
2. Decoding LY6G6D in colorectal cancer: Unraveling biomarker potential and therapeutic insights.
Naqvi M; Abbasi WA; Samma MK; Gabol AA; Innocent C; Iqbal S; Fatima S; Ali K
Cell Mol Biol (Noisy-le-grand); 2024 Jun; 70(6):14-20. PubMed ID: 38836687
[TBL] [Abstract][Full Text] [Related]
3. JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer.
Giordano G; Parcesepe P; D'Andrea MR; Coppola L; Di Raimo T; Remo A; Manfrin E; Fiorini C; Scarpa A; Amoreo CA; Conciatori F; Milella M; Caruso FP; Cerulo L; Porras A; Pancione M
J Exp Clin Cancer Res; 2019 Jan; 38(1):28. PubMed ID: 30670049
[TBL] [Abstract][Full Text] [Related]
4. LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.
Corrales L; Hipp S; Martin K; Sabarth N; Tirapu I; Fuchs K; Thaler B; Walterskirchen C; Bauer K; Fabits M; Bergmann M; Binder C; Chetta PM; Vogt AB; Adam PJ
Front Immunol; 2022; 13():1008764. PubMed ID: 36159851
[TBL] [Abstract][Full Text] [Related]
5. [Expression characteristics and clinical significance of B7-H3 in colorectal cancer].
Shao Y; Shi T; Guo L; Chen W
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 May; 40(5):435-442. PubMed ID: 38790100
[TBL] [Abstract][Full Text] [Related]
6. Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors.
Xie S; Huang J; Qiao Q; Zang W; Hong S; Tan H; Dong C; Yang Z; Ni L
Cancer Immunol Immunother; 2018 Nov; 67(11):1685-1694. PubMed ID: 30128738
[TBL] [Abstract][Full Text] [Related]
7. Novel Anti-LY6G6D/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Colorectal Cancer.
Wang P; Sun LL; Clark R; Hristopoulos M; Chiu CPC; Dillon M; Lin W; Lo AA; Chalsani S; Das Thakur M; Zimmerman Savill KM; Rougé L; Lupardus P; Piskol R; Husain B; Ellerman D; Shivva V; Leong SR; Ovacik M; Totpal K; Wu Y; Spiess C; Lee G; Leipold DD; Polson AG
Mol Cancer Ther; 2022 Jun; 21(6):974-985. PubMed ID: 35364611
[TBL] [Abstract][Full Text] [Related]
8. Gasdermin C Is Upregulated by Inactivation of Transforming Growth Factor β Receptor Type II in the Presence of Mutated Apc, Promoting Colorectal Cancer Proliferation.
Miguchi M; Hinoi T; Shimomura M; Adachi T; Saito Y; Niitsu H; Kochi M; Sada H; Sotomaru Y; Ikenoue T; Shigeyasu K; Tanakaya K; Kitadai Y; Sentani K; Oue N; Yasui W; Ohdan H
PLoS One; 2016; 11(11):e0166422. PubMed ID: 27835699
[TBL] [Abstract][Full Text] [Related]
9. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
10. Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.
Malhotra P; Anwar M; Nanda N; Kochhar R; Wig JD; Vaiphei K; Mahmood S
Tumour Biol; 2013 Jun; 34(3):1901-11. PubMed ID: 23526092
[TBL] [Abstract][Full Text] [Related]
11. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
12. Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis.
Sanz-Pamplona R; Melas M; Maoz A; Schmit SL; Rennert H; Lejbkowicz F; Greenson JK; Sanjuan X; Lopez-Zambrano M; Alonso MH; Qu C; McDonnell KJ; Idos GE; Vignali M; Emerson R; Fields P; Guinó E; Santos C; Salazar R; Robins HS; Rennert G; Gruber SB; Moreno V
PLoS Med; 2020 Sep; 17(9):e1003292. PubMed ID: 32970670
[TBL] [Abstract][Full Text] [Related]
13. KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer.
Liao W; Overman MJ; Boutin AT; Shang X; Zhao D; Dey P; Li J; Wang G; Lan Z; Li J; Tang M; Jiang S; Ma X; Chen P; Katkhuda R; Korphaisarn K; Chakravarti D; Chang A; Spring DJ; Chang Q; Zhang J; Maru DM; Maeda DY; Zebala JA; Kopetz S; Wang YA; DePinho RA
Cancer Cell; 2019 Apr; 35(4):559-572.e7. PubMed ID: 30905761
[TBL] [Abstract][Full Text] [Related]
14. Potential Therapeutic Targets of B7 Family in Colorectal Cancer.
Wang C; Feng H; Cheng X; Liu K; Cai D; Zhao R
Front Immunol; 2020; 11():681. PubMed ID: 32477326
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes.
Losi L; Di Gregorio C; Pedroni M; Ponti G; Roncucci L; Scarselli A; Genuardi M; Baglioni S; Marino M; Rossi G; Benatti P; Maffei S; Menigatti M; Roncari B; Ponz de Leon M
Am J Gastroenterol; 2005 Oct; 100(10):2280-7. PubMed ID: 16181381
[TBL] [Abstract][Full Text] [Related]
16. Proteomic profiling of a mouse model of acute intestinal Apc deletion leads to identification of potential novel biomarkers of human colorectal cancer (CRC).
Hammoudi A; Song F; Reed KR; Jenkins RE; Meniel VS; Watson AJ; Pritchard DM; Clarke AR; Jenkins JR
Biochem Biophys Res Commun; 2013 Oct; 440(3):364-70. PubMed ID: 23998936
[TBL] [Abstract][Full Text] [Related]
17. Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients.
Jeon CH; Lee HI; Shin IH; Park JW
Int J Colorectal Dis; 2008 Jan; 23(1):29-35. PubMed ID: 17704924
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer.
Lin A; Zhang J; Luo P
Front Immunol; 2020; 11():2039. PubMed ID: 32903444
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability.
Thorstensen L; Lind GE; Løvig T; Diep CB; Meling GI; Rognum TO; Lothe RA
Neoplasia; 2005 Feb; 7(2):99-108. PubMed ID: 15802015
[TBL] [Abstract][Full Text] [Related]
20. Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation.
Nakayama M; Sakai E; Echizen K; Yamada Y; Oshima H; Han TS; Ohki R; Fujii S; Ochiai A; Robine S; Voon DC; Tanaka T; Taketo MM; Oshima M
Oncogene; 2017 Oct; 36(42):5885-5896. PubMed ID: 28628120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
